AMI Asset Management Corp Has $68.37 Million Holdings in Zoetis Inc. (NYSE:ZTS)

AMI Asset Management Corp decreased its stake in Zoetis Inc. (NYSE:ZTS) by 2.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 349,945 shares of the company’s stock after selling 7,998 shares during the period. Zoetis accounts for approximately 3.7% of AMI Asset Management Corp’s holdings, making the stock its 7th largest position. AMI Asset Management Corp owned approximately 0.08% of Zoetis worth $68,372,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Prevail Innovative Wealth Advisors LLC grew its holdings in shares of Zoetis by 24.5% in the 1st quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock valued at $3,211,000 after acquiring an additional 3,738 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S grew its holdings in shares of Zoetis by 58.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock valued at $7,095,000 after acquiring an additional 15,491 shares in the last quarter. Duality Advisers LP grew its holdings in shares of Zoetis by 43.7% in the 1st quarter. Duality Advisers LP now owns 40,641 shares of the company’s stock valued at $6,877,000 after acquiring an additional 12,359 shares in the last quarter. M&G Plc bought a new position in shares of Zoetis in the 1st quarter valued at about $19,819,000. Finally, Cetera Investment Advisers grew its holdings in shares of Zoetis by 275.2% in the 1st quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after acquiring an additional 70,476 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 0.8 %

Shares of ZTS stock opened at $181.27 on Wednesday. The firm has a 50 day moving average price of $189.02 and a two-hundred day moving average price of $178.25. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $82.12 billion, a PE ratio of 34.93, a price-to-earnings-growth ratio of 2.79 and a beta of 0.89. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the business earned $1.41 earnings per share. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. As a group, analysts predict that Zoetis Inc. will post 5.83 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Stockholders of record on Thursday, October 31st will be given a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.95%. Zoetis’s payout ratio is 33.14%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus lifted their price target on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, September 18th. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Piper Sandler lifted their price target on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.